Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pitolisant for excessive daytime sleepiness in obstructive sleep apnoea patients refusing nCPAP
2009-017251-94Phase 3Completed
- Sponsor
- Bioprojet
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pitolisant in Excessive Daytime Sleepiness (EDS) and obstructive sleep apnea hypopnea syndrome (OSAHS) (4 arms), sponsored by Bioprojet. Primary endpoint: Change in Epworth Sleepiness Scale score. Started Nov 2010; status: completed.
02
Drugs
pitolisant
03
Conditions
Excessive Daytime Sleepiness (EDS)obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on 2009-017251-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017251-94.